Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
16 déc. 2024 08h00 HE
|
Senti Biosciences, Inc.
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) – SOUTH SAN...
Senti Biosciences Announces New Employment Inducement Grants
03 déc. 2024 20h00 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing
02 déc. 2024 07h10 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing...
Senti Bio Appoints Fran Schulz to Board of Directors
02 déc. 2024 07h00 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing...
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance
27 janv. 2023 08h00 HE
|
Senti Biosciences, Inc.
– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other...
Senti Bio Reports Third Quarter Financial Results and Pipeline Updates
10 nov. 2022 07h55 HE
|
Senti Biosciences, Inc.
- SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33and/or FLT3 expressing hematologic malignancies including MDS - - Selected development candidate for...
Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
06 janv. 2022 08h02 HE
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and...
Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies
20 déc. 2021 07h05 HE
|
Senti Bio
- Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common...
Senti Bio Highlights Preclinical Advances on Pipeline Candidate SENTI-202 at ASH 2021 Annual Meeting
13 déc. 2021 09h02 HE
|
Senti Bio
- Preclinical data demonstrates complete functionality of SENTI-202 OR+NOT Logic Gated gene circuits for the elimination of AML cancer cells while sparing healthy stem cells - - Presentation...
Senti Bio Highlights Colorectal Cancer Preclinical Data from Logic Gated CAR-NK Cell Program at 36th SITC Annual Meeting
12 nov. 2021 16h46 HE
|
Senti Bio
- SENTI-401 engineered to target colorectal cancer cells while sparing healthy cells - - Preclinical proof-of-concept data suggest that Logic Gated gene circuits can be used in CAR-NK cells to...